|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0023449,
umls-concept:C0205314,
umls-concept:C0596080,
umls-concept:C0679622,
umls-concept:C1332770,
umls-concept:C1514485,
umls-concept:C1533691,
umls-concept:C1567379,
umls-concept:C1879547,
umls-concept:C1999216
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-9-6
|
|
pubmed:abstractText |
Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-methyl-N-(3-(4-methylimidazol-1-yl...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CASP3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Caspases,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AllandLeilaL,
pubmed-author:ArlinghausRalph BRB,
pubmed-author:BeranMiloslavM,
pubmed-author:CortesJorgeJ,
pubmed-author:DuganMargaretM,
pubmed-author:EstrovZeevZ,
pubmed-author:GilesFrancisF,
pubmed-author:GolemovicMirnaM,
pubmed-author:KantarjianHagopH,
pubmed-author:ManleyPaulP,
pubmed-author:ManshouriTashiT,
pubmed-author:SunTongT,
pubmed-author:VerstovsekSrdanS
|
|
pubmed:copyrightInfo |
Copyright 2005 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1230-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16078266-Antineoplastic Agents,
pubmed-meshheading:16078266-Apoptosis,
pubmed-meshheading:16078266-Caspase 3,
pubmed-meshheading:16078266-Caspases,
pubmed-meshheading:16078266-Cell Cycle,
pubmed-meshheading:16078266-Cell Line, Tumor,
pubmed-meshheading:16078266-Cell Proliferation,
pubmed-meshheading:16078266-Fusion Proteins, bcr-abl,
pubmed-meshheading:16078266-Humans,
pubmed-meshheading:16078266-Phosphorylation,
pubmed-meshheading:16078266-Piperazines,
pubmed-meshheading:16078266-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:16078266-Pyrimidines
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
|
|
pubmed:affiliation |
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
